Insider · CIK 0001958621
Denise P. Carter
Files at QNRX (Quoin Pharmaceuticals, Ltd.). First filing Dec 27, 2024, latest Sep 1, 2026.
Denise P. Carter files SEC Form 4 as COO and director at QNRX (Quoin Pharmaceuticals, Ltd.). Since Dec 27, 2024, Denise P. Carter has reported 2 open-market buys worth $350k and 0 open-market sells worth $0, the latest filed on Sep 1, 2026.
A track record needs three past buys with six months of prices behind them; Denise P. Carter has 0, so none is measured yet.
The newest scored trade: bought $100k of QNRX on Aug 31, 2026, filed Sep 1, 2026, scored 55 (moderate). In the last 12 months: 1 buy worth $100k and 0 sells worth $0.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
QNRX: Quoin Pharmaceuticals, Ltd.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 55Moderate | Quoin Pharmaceuticals, Ltd. | $100k 20,490 shares | +119% | - | |
| 58Moderate | Quoin Pharmaceuticals, Ltd. | $250k 555,556 shares | +1180% | - |
Transactions
Every row this insider has filed, 9 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 31, 2026 | QNRX Quoin Pharmaceuticals, Ltd. | POpen-market purchase ADSs | +20,490 | $4.88 | $100k | 37,709 | 42 d ago |
| Aug 31, 2026 | QNRX Quoin Pharmaceuticals, Ltd. | POpen-market purchase Ordinary Warrants (Right to Buy)derivative | +10,245 | - | - | 10,245 | 42 d ago |
| Feb 4, 2026 | QNRX Quoin Pharmaceuticals, Ltd. | AGrant or award Share Option (Right to Buy)derivative | +318,750 | $0.00 | $0 | 318,750 | Feb 6, 2026 |
| May 29, 2025 | QNRX Quoin Pharmaceuticals, Ltd. | AGrant or award Share Option (Right to Buy)derivative | +42,857 | $0.00 | $0 | 42,857 | Jun 13, 2025 |
| May 29, 2025 | QNRX Quoin Pharmaceuticals, Ltd. | AGrant or award Share Option (Right to Buy)derivative | +42,039 | $0.00 | $0 | 42,039 | Jun 2, 2025 |
| Dec 23, 2024 | QNRX Quoin Pharmaceuticals, Ltd. | POpen-market purchase Ordinary Shares | +555,556 | $0.45 | $250k | 602,648 | Dec 27, 2024 |
| Dec 23, 2024 | QNRX Quoin Pharmaceuticals, Ltd. | POpen-market purchase Series F Warrants (right to buy)derivative | +555,556 | - | - | 555,556 | Dec 27, 2024 |
| Dec 23, 2024 | QNRX Quoin Pharmaceuticals, Ltd. | POpen-market purchase Series G Warrants (right to buy)derivative | +555,556 | - | - | 555,556 | Dec 27, 2024 |
| Dec 9, 2024 | QNRX Quoin Pharmaceuticals, Ltd. | AGrant or award Share Option (Right to Buy)derivative | +536,609 | $0.00 | $0 | 536,609 | Dec 10, 2024 |
Questions about Denise P. Carter
Answered from the filings on this page, as of the latest one.
Is Denise P. Carter buying or selling?
In the last 12 months Denise P. Carter reported 1 open-market buy worth $100k and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $100k of QNRX on Aug 31, 2026. Grants, option exercises and tax withholding are not counted.
How did Denise P. Carter's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Denise P. Carter has 0.
Where does Denise P. Carter file Form 4?
Denise P. Carter has filed Form 4 at QNRX (Quoin Pharmaceuticals, Ltd.) as Chief Operating Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.